Objective Fatigue is a common, multifaceted symptom in SLE which is difficult to treat. There has been a lack of broadly ...

Background Global collaboration is a key driver of advances in complex diseases such as lupus, yet its distribution and ...

Objective We aimed to characterise differences in the occurrence of maternal cardiovascular events (CVEs) and adverse ...

The association between SLE and composite stroke, ischaemic stroke and haemorrhagic stroke remains incompletely understood. This meta-analysis aims to assess the risk of stroke in patients with ...

Objectives DNASE1L3 deficiency is a rare monogenic cause of early-onset SLE and hypocomplementaemic urticarial vasculitis ...

Objective To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate ...

Introduction Lupus nephritis (LN) exhibits substantial clinical and pathological heterogeneity. We aimed to define proteomics-based molecular subtypes of LN and identify candidate biomarkers for ...

Objective To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), ...

Objective Hydroxychloroquine (HCQ) is an antimalarial drug employed in the treatment of systemic lupus erythematosus (SLE). Prior studies reported inconsistent results regarding the association ...

Objective Primary immune thrombocytopaenia (ITP) is highly heterogeneous. ANA-positive primary ITP may resemble the preclinical stage of connective tissue diseases (CTDs), but is still considered ...

Objective To estimate the prevalence of organ damage (damage) and flare and to examine longitudinal associations between flares and subsequent damage accrual, in patients with systemic lupus ...

Objectives Cardiovascular disease is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE), largely driven by endothelial dysfunction. Belimumab, a monoclonal antibody ...